StocksFundsScreenerSectorsWatchlists
CRIS

CRIS - Curis Inc Stock Price, Fair Value and News

10.63USD-0.24 (-2.21%)Delayed as of 28 Mar 2024, 11:06 am ET

Market Summary

CRIS
USD10.63-0.24
Delayedas of 28 Mar 2024, 11:06 am
-2.21%

CRIS Stock Price

View Fullscreen

CRIS RSI Chart

CRIS Valuation

Market Cap

64.1M

Price/Earnings (Trailing)

-1.35

Price/Sales (Trailing)

6.39

Price/Free Cashflow

-1.67

CRIS Price/Sales (Trailing)

CRIS Profitability

Return on Equity

-241.04%

Return on Assets

-61.35%

Free Cashflow Yield

-59.94%

CRIS Fundamentals

CRIS Revenue

Revenue (TTM)

10.0M

Rev. Growth (Yr)

-6.62%

Rev. Growth (Qtr)

-4.84%

CRIS Earnings

Earnings (TTM)

-47.4M

Earnings Growth (Yr)

-3.38%

Earnings Growth (Qtr)

3.85%

Breaking Down CRIS Revenue

52 Week Range

10.70
(Low)(High)

Last 7 days

4.9%

Last 30 days

3.0%

Last 90 days

-21.6%

Trailing 12 Months

1900%

How does CRIS drawdown profile look like?

CRIS Financial Health

Current Ratio

4.51

CRIS Investor Care

Shares Dilution (1Y)

22.02%

Diluted EPS (TTM)

-8.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202310.4M10.2M10.2M10.0M
202210.5M10.6M10.4M10.2M
202110.3M10.2M10.5M10.6M
202010.9M11.2M11.1M10.8M
20199.7M9.5M9.5M10.0M
201810.2M10.5M10.9M10.4M
20177.9M8.3M9.0M9.9M
20167.9M7.5M7.3M7.5M
201510.2M7.5M7.8M7.9M
201415.4M14.8M9.4M9.8M
20137.5M8.5M15.2M15.0M
201219.6M24.5M29.4M17.0M
201115.7M15.4M15.1M14.8M
2010011.1M13.5M16.0M
20090008.6M

Tracking the Latest Insider Buys and Sells of Curis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 31, 2022
dentzer james e
sold
-9,498
3.07
-3,094
president & ceo
Jan 27, 2022
dentzer james e
sold
-7,651
3.18
-2,406
president & ceo
Jan 26, 2021
dentzer james e
sold
-32,758
10.5876
-3,094
president & ceo
Jan 25, 2021
dentzer james e
sold
-25,021
10.96
-2,283
president & ceo
Jan 24, 2020
dentzer james e
sold
-5,076
1.6407
-3,094
president & ceo
Jan 23, 2020
dentzer james e
sold
-6,181
1.6899
-3,658
president & ceo
Jan 24, 2019
dentzer james e
sold
-3,576
1.1561
-3,094
president & ceo
Jan 23, 2019
greenacre martyn d
sold
-19,474
1.0527
-18,500
-
Jan 23, 2019
kaitin kenneth i
sold
-15,587
1.0532
-14,800
-
Jan 23, 2019
dentzer james e
sold
-2,612
1.09
-2,397
president & ceo

1–10 of 14

Which funds bought or sold CRIS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 18, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.
added
83.83
5,208,530
7,245,830
0.45%
Mar 11, 2024
VANGUARD GROUP INC
added
15.9
1,472,710
2,658,070
-%
Mar 04, 2024
VIMA LLC
new
-
38.00
38.00
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
new
-
740
740
-%
Feb 14, 2024
COMERICA BANK
unchanged
-
616
1,275
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
unchanged
-
18.00
38.00
-%
Feb 14, 2024
LM Advisors LLC
new
-
2,550
2,550
-%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
sold off
-100
-145,830
-
-%
Feb 14, 2024
Alyeska Investment Group, L.P.
sold off
-100
-514,910
-
-%
Feb 14, 2024
LPL Financial LLC
new
-
154,046
154,046
-%

1–10 of 43

Are Funds Buying or Selling CRIS?

Are funds buying CRIS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRIS
No. of Funds

Unveiling Curis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
maverick capital ltd
9.9%
582,273
SC 13G/A
Feb 12, 2024
m28 capital management lp
7.2%
421,951
SC 13G
Feb 14, 2023
maverick capital ltd
5.8%
5,555,598
SC 13G/A
Jan 20, 2023
state street corp
0.26%
255,009
SC 13G/A
Jul 08, 2022
blackrock inc.
2.6%
2,359,787
SC 13G
Feb 14, 2022
point72 asset management, l.p.
1.6%
1,442,543
SC 13G/A
Feb 14, 2022
maverick capital ltd
8.5%
7,790,478
SC 13G
Feb 11, 2022
state street corp
8.51%
7,799,328
SC 13G
Feb 04, 2022
blackrock inc.
6.9%
6,281,041
SC 13G
Nov 15, 2021
ra capital management, l.p.
0%
0
SC 13G/A

Recent SEC filings of Curis Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 08, 2024
S-8
Employee Benefits Plan
Feb 08, 2024
S-3
S-3
Feb 08, 2024
8-K
Current Report
Feb 08, 2024
10-K
Annual Report
Jan 11, 2024
8-K
Current Report
Jan 03, 2024
UPLOAD
UPLOAD
Dec 21, 2023
10-K/A
Annual Report
Dec 21, 2023
CORRESP
CORRESP

Peers (Alternatives to Curis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Curis Inc News

Latest updates
MarketBeat22 Mar 202408:38 am
Defense World22 Mar 202408:35 am
Yahoo Finance09 Feb 202408:00 am
Seeking Alpha08 Feb 202408:00 am
PR Newswire08 Feb 202408:00 am

Curis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-4.8%2,6962,8332,1972,2972,8872,8252,3932,0573,1353,0392,2862,1893,0242,7422,3602,7093,2872,8562,0941,7672,755
Costs and Expenses-2.0%14,89515,20114,33513,92413,10715,43117,45417,19015,70213,08712,93610,9899,2997,4537,79011,19110,6218,1798,2357,3257,903
  S&GA Expenses2.4%4,8774,7614,2494,7604,3304,5565,0895,6734,7734,3344,0674,1233,5392,6132,3863,5932,9992,8872,5263,1433,044
Interest Expenses-75.8%1827537636611,0191,0021,0171,0741,0801,0521,1121,193-2,443--1,062---791936
Net Income3.9%-11,712-12,181-11,961-11,559-11,329-13,294-15,940-16,109-13,620-11,051-10,838-9,927-7,517-5,974-6,708-9,709-8,609-6,436-7,213-9,884-5,941
Net Income Margin-2.7%-4.73*-4.60*-4.72*-5.01*-5.58*-5.66*-5.34*-4.91*-4.27*-3.73*-3.34*-2.92*---------
Free Cashflow-24.1%-10,152-8,181-7,900-12,200-12,231-13,174-12,485-16,826-8,171-9,610-6,659-13,179---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-14.1%77.0090.0084.0095.0010912312914116217218119120446.0045.0027.0035.0042.0048.0055.0037.00
  Current Assets-17.0%61.0073.0068.0078.0092.0010611312612213515716217328.0027.0017.0025.0033.0038.0045.0028.00
    Cash Equivalents9.0%27.0024.0020.0032.0020.0030.0035.0019.0041.0054.0076.0011213024.0025.0014.0016.0021.0027.0043.0024.00
  Net PPE-12.7%0.000.001.001.001.001.001.000.001.001.001.001.001.001.001.000.000.000.000.000.000.00
  Goodwill0%9.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.009.00
Liabilities-4.6%58.0060.0058.0058.0062.0067.0067.0065.0072.0069.0069.0069.0074.0074.0075.0067.0069.0068.0069.0069.0042.00
  Current Liabilities-1.4%14.0014.0010.008.0010.0014.0012.0010.0013.009.008.007.0010.009.009.006.007.005.004.005.0013.00
  Long Term Debt-------------0.001.000.00-----29.00
    LT Debt, Current------------1.001.000.000.00-----7.00
    LT Debt, Non Current-------------0.001.000.00-----29.00
Shareholder's Equity-33.5%20.0030.0026.0037.0047.0056.0062.0076.0091.00103112122131--------
  Retained Earnings-1.0%-1,196-1,184-1,200-1,200-1,149-1,100-1,100-1,108-1,092-1,078-1,067-1,056-1,046-1,000-1,000-1,026-1,016-1,000-1,001-994-984
  Additional Paid-In Capital0.1%1,2161,2141,1981,1961,1961,1931,1861,1841,1821,1811,1791,1781,1771,0101,003986983982981981980
Shares Outstanding0.1%6.006.005.005.005.005.005.005.005.005.005.005.00---------
Float---82.00---90.00---737---54.00---51.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-24.1%-10,152-8,181-7,867-12,200-12,268-13,122-12,132-16,815-8,171-9,610-6,659-13,179-5,715-5,877-5,131-9,016-5,599-6,704-6,669-7,233-4,940
  Share Based Compensation-5.2%1,5481,6331,4241,3951,7441,3241,9661,7181,4411,4641,2751,099865623585625692684631651631
Cashflow From Investing7965.0%14,517180-3,15426,2433,4634,30328,340-3,083-3,523-11,530-28,771-4,071-53,469-162-2584,8411,5491,453-8,0586004,654
Cashflow From Financing-116.9%-2,11812,556-852-2,006-1,3884,662-759-1,648-1,312-956-575-1,329165,2395,82016,4781,277-1,061-611-82025,763-1,639

CRIS Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues, net:  
Revenues, net$ 10,023$ 10,162
Operating expenses:  
Cost of royalties212257
Research and development39,49643,277
General and administrative18,64719,648
Total operating expenses58,35563,182
Loss from operations(48,332)(53,020)
Other income (expense):  
Interest income2,9381,119
Expense related to the sale of future royalties(2,019)(4,771)
Total other income (expense)919(3,652)
Net loss$ (47,413)$ (56,672)
Net loss per common share, basic (in dollars per share)$ (8.96)$ (12.14)
Net loss per common share, diluted (in dollars per share)$ (8.96)$ (12.14)
Weighted average common shares, basic (in shares)5,293,2944,669,626
Weighted average common shares, diluted (in shares)5,293,2944,669,626
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]  
Net loss$ (47,413)$ (56,672)
Other comprehensive income (loss):  
Unrealized gain (loss) on marketable securities415(77)
Comprehensive loss$ (46,998)$ (56,749)

CRIS Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 26,681$ 19,658
Short-term investments29,65365,965
Accounts receivable2,7942,975
Prepaid expenses and other current assets1,7803,521
Total current assets60,90892,119
Property and equipment, net434689
Restricted cash, long-term544635
Operating lease right-of-use asset3,0564,401
Other assets3,3582,022
Goodwill8,9828,982
Total assets77,282108,848
Current liabilities:  
Accounts payable3,1723,193
Accrued liabilities9,0405,679
Current portion of operating lease liability1,3051,141
Total current liabilities13,51710,013
Long-term operating lease liability1,4892,800
Liability related to the sale of future royalties, net42,60649,483
Total liabilities57,61262,296
Commitments and contingencies, Note 7
Stockholders’ equity:  
Preferred stock, $0.01 par value—5,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 202200
Common stock, $0.01 par value—22,781,250 shares authorized, 5,894,085 shares issued and outstanding at December 31, 2023; 11,390,625 shares authorized, 4,830,464 shares issued and outstanding at December 31, 20225948
Additional paid-in capital1,215,7921,195,687
Accumulated deficit(1,196,410)(1,148,997)
Accumulated other comprehensive gain (loss)229(186)
Total stockholders’ equity19,67046,552
Total liabilities and stockholders’ equity$ 77,282$ 108,848
CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEwww.curis.com
 EMPLOYEES51

Curis Inc Frequently Asked Questions


What is the ticker symbol for Curis Inc? What does CRIS stand for in stocks?

CRIS is the stock ticker symbol of Curis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Curis Inc (CRIS)?

As of Wed Mar 27 2024, market cap of Curis Inc is 64.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers.

What is the fair value of CRIS stock?

You can check CRIS's fair value in chart for subscribers. The fair value of Curis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Curis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRIS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Curis Inc a good stock to buy?

The fair value guage provides a quick view whether CRIS is over valued or under valued. Whether Curis Inc is cheap or expensive depends on the assumptions which impact Curis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRIS.

What is Curis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, CRIS's PE ratio (Price to Earnings) is -1.35 and Price to Sales (PS) ratio is 6.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRIS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Curis Inc's stock?

In the past 10 years, Curis Inc has provided -0.035 (multiply by 100 for percentage) rate of return.